title: Bone cancer in 2011: Prevention and treatment of bone metastases.
abstract: Bone-targeting treatments have transformed the quality of life of patients with metastatic bone disease. 2011 saw the emergence of denosumab—a RANK ligand-specific antibody—as a more-effective alternative treatment to bisphosphonates and of data on the use of bone-targeting treatments to prevent metastasis from breast and prostate cancers.
authors.affiliation: Sheffield Cancer Research Center, Academic Unit of Clinical Oncology, Weston Park Hospital, Whitham Road, Sheffield S10 2SJ, UK. r.e.coleman@sheffield.ac.uk
authors.forename: Robert E
authors.initials: RE
authors.lastname: Coleman
mesh_terms: D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000517:prevention & control* / Q000556:secondary*; D002986:Clinical Trials as Topic; D004164:Diphosphonates / Q000627:therapeutic use*; D049674:History, 21st Century; D006801:Humans
chemical_list: D050071:Bone Density Conservation Agents; D004164:Diphosphonates